Bhatia A et al. Tumor volume growth rates and doubling times during active surveillance of IDH-mutant low-grade glioma. Clin Cancer Res 2024;30(1):106-15. Abstract
Bunse L et al. Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate. Nat Med 2018;24(8):1192-203. Abstract
de la Fuente MI et al. Olutasidenib (FT-2102) in patients with relapsed or refractory IDH1-mutant glioma: A multicenter, open-label, phase Ib/II trial. Neuro Oncol 2023;25(1):146-56. Abstract
Harvey-Jumper SL et al. Interactive effects of molecular, therapeutic, and patient factors on outcome of diffuse low-grade glioma. J Clin Oncol 2023;41(11):2029-42. Abstract
Lassman AB et al. Joint final report of EORTC 26951 and RTOG 9402: Phase III trials with procarbazine, lomustine, and vincristine chemotherapy for anaplastic oligodendroglial tumors. J Clin Oncol 2022;40(23):2539-45. Abstract
Mellinghoff IK et al. A global, randomized, double-blinded, phase 3 study of vorasidenib versus placebo in patients with adult-type diffuse glioma with an IDH1/2 mutation (INDIGO): Updated efficacy results. SNO 2024;Abstract CTNI-53.
Mellinghoff IK et al. Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: A randomized, perioperative phase 1 trial. Nat Med 2023;29(3):615-22. Abstract
Mellinghoff IK et al. Vorasidenib in IDH1- or IDH2-mutant low-grade glioma. N Engl J Med 2023;389(7):589-601. Abstract
Mellinghoff IK et al. Vorasidenib, a dual inhibitor of mutant IDH1/2, in recurrent or progressive glioma; Results of a first-in-human phase I trial. Clin Cancer Res 2021;27(16):4491-9. Abstract
Natsume A et al. The first-in-human phase I study of a brain-penetrant mutant IDH1 inhibitor DS-1001 in patients with recurrent or progressive IDH1-mutant gliomas. Neuro Oncol 2023;25(2):326-36. Abstract
Peters K et al. A randomized, double-blind, phase 3 study of vorasidenib versus placebo in patients with mutant IDH1/2 diffuse glioma (INDIGO): Analysis of health-related quality of life, neurocognition and seizures. AAN 2024;Abstract PL5.003.
Platten M et al. A vaccine targeting mutant IDH1 in newly diagnosed glioma. Nature 2021;592(7854):463-8. Abstract
Reuss DE et al. IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: A grading problem for WHO. Acta Neuropathol 2015;129(6):867-73. Abstract
van den Bent MJ et al. The biological significance of tumor grade, age, enhancement, and extent of resection in IDH-mutant gliomas: How should they inform treatment decisions in the era of IDH inhibitors? Neuro Oncol 2024;26(10):1805-22. Abstract
Weller M et al. EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol 2021;18(3):170-86. Abstract
Wen P et al. A phase 1, safety lead-in and randomized, open-label, perioperative study of vorasidenib combined with pembrolizumab in recurrent or progressive enhancing IDH-1 mutant glioma: Trial in progress. SNO 2023;Abstract CTIM-19.